Safety and Side Effects of Rifampin versus Isoniazid in Children

2018159 citationsJournal Articlebronze Open Access

Authors

Thierno Diallo · Gamal Abdel Nasser University of Conakry

Mênonli Adjobimey · Centre National Hospitalier et Universitaire Hubert Koutoukou MAGA

Rovina Ruslami · Padjadjaran University

Anete Trajman · Universidade do Estado do Rio de Janeiro

Oumou Bah Sow · Gamal Abdel Nasser University of Conakry

Joseph Obeng Baah · Komfo Anokye Teaching Hospital

Guy B. Marks

Abstract

Among children under the age of 18 years, treatment with 4 months of rifampin had similar rates of safety and efficacy but a better rate of adherence than 9 months of treatment with isoniazid. (Funded by the Canadian Institutes of Health Research and Conselho Nacional de Pesquisa; ClinicalTrials.gov number, NCT00170209 .).

Topics & Keywords

Tuberculosis Research and Epidemiology Drug-Induced Hepatotoxicity and Protection Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-beingNo poverty

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 5, pp. 454-463

DOI: 10.1056/nejmoa1714284

Field-Weighted Citation Impact: 11.27